From DCAT Value Chain Insights (VCI)
AMRI reports that Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI. Mr. Nolan will remain with AMRI through February 2015 to support an orderly transition. The company also announced that Felicia Ladin will join the company in the same role, effective February 4, 2015.
Ms. Ladin brings more than 20 years of finance, accounting and tax management experience to AMRI. A CPA by training, Ladin has spent the majority of her career in the pharmaceutical industry, most recently as senior vice president, CFO, Global Specialty Medicines at Teva Pharmaceuticals, USA. Between 2008 and 2014, Ms. Ladin held positions of increasing responsibility directing Teva's financial planning and analysis operations, and from 2002 to 2008 was tax director for the US. During her 12 year tenure at Teva, Ladin was instrumental in developing and implementing financial systems and infrastructure through a number of acquisitions, and driving consistency and efficiencies across locations, supporting the Specialty Medicine division's growth into an $8 billion global business.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription